DOSSIER · UPDATED 18 NOV 2025

Invitae

Genetic insights can change everything

www.invitae.com ↗Claim this profile

Founded: 2010
Headcount: 735
Open roles: 0
Last raised: Post Ipo Debt · $1.1B

SECTION I · THE BRIEF

Inside Invitae

Brief #87920Updated 18 NOV 2025SAN FRANCISCOSAN FRANCISCOPOST IPO DEBT

Employbl Dossier

Invitae

Genetic insights can change everything

Founded: 2010
Headcount: 735
Open roles: 0
Last raised: Post Ipo Debt · $1.1B

Section II — RestrictedMembers only

Engineering interview process at Invitae
Tech stack & infrastructure choices
Culture & day-to-day work style
Why join now vs. 6 months from now
Hiring focus & open headcount by team
Comp philosophy and band context

Open Invitae brief Sign in

7-day free trial · $25/mo · cancel anytime

LEADERSHIP

Founders & key people

Randy Scott

Alex Furman

OPEN ROLES

Hiring at Invitae

Current Job Listings

Listing 0 of 0 job openings

We don't currently have any jobs listed for this company. We suggest visiting the Jobs Search page if you are looking for exciting new tech and startup opportunities.

FUNDING

Capital raised

Total Amount Raised: $2,679,202,048

Invitae Funding Rounds

Post Ipo Debt
$1,150,000,000
Apr 5, 2021
Post Ipo Debt
$1,150,000,000
Apr 4, 2021
Post Ipo Debt Investors
Softbank
Post Ipo Equity
$460,000,000
Jan 20, 2021
Post Ipo Equity
$460,000,000
Jan 19, 2021
Post Ipo Equity
$184,000,000
Apr 1, 2020
Post Ipo Equity
$184,000,000
Mar 31, 2020
Post Ipo Debt
$300,000,000
Sep 6, 2019
Post Ipo Debt
$300,000,000
Sep 5, 2019
Post Ipo Equity
$196,700,000
Mar 31, 2019
Post Ipo Equity
$196,700,000
Mar 30, 2019
Post Ipo Equity
$75,000,000
Aug 9, 2018
Post Ipo Equity
$75,000,000
Aug 8, 2018
Post Ipo Equity
$75,000,000
Mar 26, 2018
Post Ipo Equity
$74,000,000
Jul 31, 2017
Post Ipo Equity
$74,000,000
Jul 30, 2017
Post Ipo Secondary
$44,000,000
Nov 17, 2016
Post Ipo Secondary
$44,000,000
Nov 16, 2016
IPO
Unknown
Feb 12, 2015
IPO
Unknown
Jan 1, 2015
Series F
$120,000,000
Oct 13, 2014
Series F
$120,000,000
Oct 12, 2014
Series F Investors
Three Leaf Ventures
Decheng Capital
Deerfield Capital Management
OrbiMed Advisors
Perceptive Advisors
Rock Springs Capital
Wellington Management
Casdin Capital
Genesys Capital
Genomic Health
Sofinnova Ventures
Redmile Group
Thomas McNerney & Partners
J.P. Morgan Securities
Series E
$40,000,000
Dec 10, 2013
Series E
$40,000,000
Dec 9, 2013
Series E Investors
Genomic Health
Genesys Capital
Casdin Capital
Redmile Group
Sofinnova Ventures
Series A
$29,557,113
Nov 8, 2012
Series A
$29,557,113
Nov 7, 2012
Series Unknown
$2,299,999
Mar 29, 2011
Series Unknown
$2,299,999
Mar 28, 2011
Series Unknown
$3,644,999
Sep 15, 2010
Series Unknown
$3,644,999
Sep 14, 2010
Series Unknown Investors
Anya Schiess